 Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in its infringement lawsuit against Clarus Therapeutics, Inc. Clarus in the United States District Court Delaware related to the infringement of six Lipocine U.S. Patents by Claruss JATENZO product, Lipocine has voluntarily dismissed its allegations of patent infringement for expired U.S. Patent Nos. 6,569,463 and 6,923,988. Lipocine continues to vigorously defend its patent rights and maintains its allegations for patent infringement of four U.S. patents U.S. patent nos. 9,034,858; 9,205,057; 9,480,690; and 9,757,390 by Claruss JATENZO product, which has yet to launch. 